Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : US authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing

07/30/2021 | 10:42am EDT
FILE PHOTO: A woman holds a test tube in front of displayed Emergent logo in this illustration

WASHINGTON, July 30 (Reuters) - Drug manufacturer Emergent BioSolutions Inc said on Friday it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.

Emergent came under regulatory scrutiny after an error led to millions of vaccine doses being ruined at its manufacturing facility in Baltimore, which was producing bulk drug substance for Johnson & Johnson's COVID-19 vaccine.

The U.S. Food and Drug Administration (FDA) in April halted operations at the plant after it discovered that ingredients from AstraZeneca's COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.

Emergent in a filing https://investors.emergentbiosolutions.com/node/20661/html on Friday said it has received "preliminary inquiries and subpoenas to produce documents" from the lawmakers, the Department of Justice, the Securities and Exchange Commission, the Financial Industry Regulatory Authority, and Maryland and New York Attorneys General.

The Department of Justice declined to comment on the matter.

Emergent said it was producing and has produced documents as required in response and will continue to cooperate with the government inquiries.

An FDA inspection in April turned up a long list of sanitary problems and bad manufacturing practices at the facility, including failure to train personnel to avoid cross contamination of COVID-19 vaccines from J&J and AstraZeneca.

Emergent said on Wednesday production at the Baltimore facility will now resume, following remedial actions, additional reviews and collaboration with the FDA and its manufacturing partners.

An FDA spokesperson said on Thursday the facility has not yet received any authorization for a COVID-19 vaccine, but may produce vaccine substance in advance of future inspections by the health regulator. (Reporting by Chris Prentice in Washington and Manojna Maddipatla in Bengaluru; Editing by Bernard Orr and Shounak Dasgupta)

ę Reuters 2021
All news about ASTRAZENECA PLC
08:42aASTRAZENECA : Credit Suisse maintains a Buy rating
08:26aSANOFI : - New research presented at IDWeek 2021 reinforces Sanofi :'s robust vaccines pip..
07:50aASTRAZENECA : Receives a Buy rating from Jefferies
07:06aASTRAZENECA : 300,000 Covid-19 Jabs Land in Namibia
06:32aASTRAZENECA : Saphnelo is a first-in-class type I interferon receptor antibody shown to re..
06:06aASTRAZENECA : Ghana Takes Custody of 1.5 Astrazeneca Doses Donation From Germany
05:06aASTRAZENECA : Govt - 4.7 Million Eligible Nigerians Have Received First Dose of Covid-19 V..
04:15aASTRAZENECA : Secures Japanese Regulatory Approval for Saphnelo as Treatment for Systemic ..
03:06aASTRAZENECA : Covid-19 - Govt Says 1.8m Nigerians Fully Vaccinated
02:31aASTRAZENECA : Lupus Drug Gets Japanese Approval
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 524 M - -
Net income 2021 5 008 M - -
Net Debt 2021 24 280 M - -
P/E ratio 2021 32,9x
Yield 2021 2,40%
Capitalization 182 B 182 B -
EV / Sales 2021 5,80x
EV / Sales 2022 4,71x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 117,38 $
Average target price 136,22 $
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC16.97%181 937
JOHNSON & JOHNSON3.68%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.19.37%244 283
NOVO NORDISK A/S48.08%227 557